کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2167444 | 1092332 | 2011 | 8 صفحه PDF | دانلود رایگان |
A phase II trial was conducted in subjects with human papillomavirus (HPV) associated high-grade cervical dysplasia testing the safety and efficacy of a microparticle encapsulated pDNA vaccine. Amolimogene expresses T cell epitopes from E6 and E7 proteins of HPV types 16 and 18. An analysis was performed on a subset of HLA-A2+ subjects to test whether CD8+ T cells specific to HPV 16, 18, 6 and 11 were increased in response to amolimogene immunization. Of the 21 subjects receiving amolimogene, 11 had elevated CD8+ T cell responses to HPV 16 and/or 18 peptides and seven of these also had increases to corresponding HPV 6 and/or 11 peptides. In addition, T cells primed and expanded in vitro with an HPV 18 peptide demonstrated cross-reactivity to the corresponding HPV 11 peptide. These data demonstrate that treatment with amolimogene elicits T cell responses to HPV 16, 18, 6 and 11.
► Immunization with amolimogene induces T cells specific to HPV in HSIL subjects.
► Amolimogene expresses T cell epitopes from E6/E7 proteins of HPV types 16 and 18.
► 7 of 11 subjects with amolimogene induced HPV 16/18 T cells, responded to HPV 6/11.
► An HPV 18 T cell line can recognize the HPV 11 peptide used in our studies.
Journal: Cellular Immunology - Volume 270, Issue 1, 2011, Pages 62–69